![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 13, Issue 5, 1449-1461, May 2002


and
§
Molecular Oncology Group, McGill University Hospital Center,
Departments of *Biochemistry,
Medicine and
§Oncology, McGill University, Montreal, Quebec, Canada H3A
1A1
| |
ABSTRACT |
|---|
|
|
|---|
Activation of the Met receptor tyrosine kinase through its ligand, hepatocyte growth factor (HGF), promotes an epithelial-mesenchymal transition and cell dispersal. However, little is known about the HGF-dependent signals that regulate these events. HGF stimulation of epithelial cell colonies leads to the enhanced recruitment of the CrkII and CrkL adapter proteins to Met-dependent signaling complexes. We provide evidence that signals involving CrkII and CrkL are required for the breakdown of adherens junctions, the spreading of epithelial colonies, and the formation of lamellipodia in response to HGF. The overexpression of a CrkI SH3 domain mutant blocks these HGF-dependent events. In addition, the overexpression of CrkII or CrkL promotes lamellipodia formation, loss of adherens junctions, cell spreading, and dispersal of colonies of breast cancer epithelial cells in the absence of HGF. Stable lines of epithelial cells overexpressing CrkII show enhanced activation of Rac1 and Rap1. The Crk-dependent breakdown of adherens junctions and cell spreading is inhibited by the expression of a dominant negative mutant of Rac1 but not Rap1. These findings provide evidence that Crk adapter proteins play a critical role in the breakdown of adherens junctions and the spreading of sheets of epithelial cells.
| |
INTRODUCTION |
|---|
|
|
|---|
The acquisition of a mesenchymal phenotype by
epithelial cells, a process termed epithelial-mesenchymal (EM)
transition (Boyer et al., 2000
), is required for
morphogenesis and tissue remodeling during development (Guarino, 1995
).
EM transitions are regulated in part through the actions of growth
factors, the extracellular matrix, and cell-cell adhesion proteins
(Prieto and Crossin, 1995
; Boyer et al., 2000
). Although
tightly controlled during development, nonscheduled EM transitions in
the adult organism can lead to the development and progression of human
malignancies. In some cancers, this occurs through downregulation or
mutation of E-cadherin or
-catenin (Behrens, 1999
). In addition, the
dissolution of cadherin-based junctional complexes is also promoted by
growth factors and their receptors and oncogenes such as Ras (Boyer
et al., 2000
).
Hepatocyte growth factor (HGF) is a multifunctional factor, which, in
addition to promoting epithelial cell growth and survival (Matsumoto
and Nakamura, 1997
), is a potent modulator of EM transition (Weidner
et al., 1993
; Zhu et al., 1994
). In
two-dimensional cultures, HGF stimulates the breakdown of cell-cell
junctions and dispersal of sheets of epithelial cells, increasing their
invasiveness (Stoker et al., 1987
; Weidner et
al., 1990
). HGF and its receptor, the Met receptor tyrosine
kinase, are deregulated or overexpressed in many human tumors (Lamorte
and Park, 2001
). For example, amplification of the Met receptor
tyrosine kinase has been found in gastric carcinomas (Nakajima et
al., 1999
) and gliomas (Koochekpour et al., 1997
).
Activating point mutations within the kinase domain of the Met receptor
tyrosine kinase have been characterized in hereditary and sporadic
papillary renal carcinomas (Schmidt et al., 1997
). Moreover,
overexpression of HGF and/or the Met receptor is associated with a poor
prognosis for breast cancer patients (Jin et al., 1997
;
Ghoussoub et al., 1998
; Camp et al., 1999
) and
transgenic mice overexpressing HGF develop tumors with metastatic lesions (Takayama et al., 1997
; Otsuka et al.,
1998
). These results underscore the importance of defining the
mechanisms involved in promoting HGF-dependent EM transitions.
At the cellular level, stimulation of the Met receptor tyrosine kinase
induces the remodeling of the actin cytoskeleton, cell spreading, and
the breakdown of cell-cell junctions (Ridley et al., 1995
;
Royal and Park, 1995
; Potempa and Ridley, 1998
; Royal et
al., 2000
). Rac1 and Cdc42 are small GTP binding proteins involved in the remodeling of the actin cytoskeleton (Hall, 1998
) and are activated in response to HGF (Royal et al., 2000
). Rac1
mediates the formation of lamellipodia and membrane ruffles, whereas
Cdc42 regulates the formation of filopodia (Hall, 1998
). Both Rac1 and Cdc42 are critical for the spreading of Madin-Darby canine kidney (MDCK) epithelial cells stimulated with HGF (Ridley et al.,
1995
; Royal et al., 2000
). Rac1 activation in response to
HGF is dependent on phosphatidylinositol 3'-kinase (PI3K), as
the pretreatment of cells with inhibitors of PI3K blocks HGF-stimulated
activation of Rac1, cell spreading, and dispersal (Royal and Park,
1995
; Royal et al., 2000
). In addition, inhibition of PI3K
prevents the breakdown of adherens junctions after the stimulation of
MDCK cells with HGF (Royal and Park, 1995
; Potempa and Ridley, 1998
).
Studies using different model systems have shown that overexpression of
CrkII or CrkL enhances cell migration (Klemke et al., 1998
;
Uemura and Griffin, 1999
; Cho and Klemke, 2000
; Petit et al., 2000
; Spencer et al., 2000
). The CrkII adapter
protein was originally identified as a viral oncogene, v-crk
(Mayer et al., 1988
) and is composed of one Src homology 2 (SH2) and two Src homology 3 (SH3) domains (SH2-SH3-SH3; Reichman
et al., 1992
). A second Crk-like gene, CrkL, was later
isolated and it contains a similar modular structure as CrkII (ten
Hoeve et al., 1993
). The Crk SH2 domain binds several
tyrosine-phosphorylated proteins: p130Cas, paxillin, Cbl, and Gab1
(Feller, 2001
), whereas the amino terminal SH3 domain binds C3G,
DOCK180, and Abl (Feller, 2001
). More recently, it was shown that
DOCK180 can bind and activate Rac1 (Kiyokawa et al., 1998
;
Nolan et al., 1998
), and genetic studies in
Caenorhabditis elegans have demonstrated a role for CrkII
and DOCK180 in the activation of Rac1 and cell migration (Reddien and
Horvitz, 2000
).
Although previous studies have examined the involvement of CrkII or CrkL in the migration of single cells, they did not address the involvement of CrkII or CrkL in the dispersal of sheets of epithelial cells, an event critical for metastasis. We demonstrate a role for CrkII and CrkL in the formation of lamellipodia, the spreading of colonies, and the breakdown of adherens junctions in epithelial MDCK cells in response to HGF. In addition, we show that in the absence of HGF, CrkII, or CrkL overexpression promotes lamellipodia formation, cell spreading, and the breakdown of adherens junctions in MDCK cells and cell dispersal in well-differentiated breast carcinoma cells.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials and Antibodies
HGF was provided by Dr. George Vande Woude (Van Andel Research Institute, Grand Rapids, MI), and Dr. Michel Tremblay (McGill University) provided a polyclonal p130Cas antibody. Crk antibodies recognizing both CrkI and CrkII were purchased from BD Transduction Laboratories (Lexington, KY). Crk antibodies raised against either CrkII (C-18) or CrkL (C-20) along with Cbl, C3G, and Rap1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Paxillin and Rac1 antibodies and a phosphotyrosine antibody conjugated to horseradish peroxidase (RC20H) were purchased from BD Transduction Laboratories. HA.11 and c-Myc (9E10) antibodies were obtained from Berkley Antibody Company (Berkley, CA). ZO-1 antibodies were purchased from Zymed Laboratories, Inc. (South San Francisco, CA). Vinculin antibodies were purchased from Sigma (Oakville, ON, Canada). AlexaFluor488 phalloidin, Texas Red-X phalloidin, and secondary antibodies conjugated to AlexaFluor488 were purchased from Molecular Probes (Eugene, OR). Secondary antibodies conjugated to CY3 were obtained from Jackson ImmunoResearch Labs (West Grove, PA). All molecular biology products were purchased from New England BioLabs Inc. (Mississauga, ON, Canada).
Plasmids
Dr. Bruce Mayer (University of Connecticut Health Center, Farmington, CT) provided pEBB, pEBB-CrkI W170K, pEBB-CrkI R38K/W170K, and pEBB-Crk II. CrkII was subcloned as a BamHI/NotI fragment into pLXSH and used for retroviral infection of T47D cells. Dr. John Groffen (Children's Hospital of Los Angeles Research Institute, Los Angeles, CA) provided SV40-CrkL. Dr. Michel Tremblay (McGill University) provided pcDNA3-p130Cas. Dr. Alan Hall (University College London, London, United Kingdom) provided pRK5-mycN17Rac1 and pRK5-mycN17Rap1.
Cell Culture
MDCK and T47D cells were maintained in DMEM containing 10%
fetal bovine serum (FBS) and 50 µg/ml gentamicin (Invitrogen Canada Inc., Burlington, ON, Canada). To generate MDCK cells overexpressing CrkII, cells were transfected in a six-well plate with 1.8 µg of
pEBB-CrkII and 200 ng of pSV2neo using GenePorter (Gene Therapy Systems, San Diego, CA). Cells were selected in 400 µg/ml Geneticin (Invitrogen Canada Inc.), and stable clones were isolated and screened
by Western blotting. Populations of T47D cells expressing CrkII or
empty vector were obtained by retroviral infection with pLXSH-CrkII or
pLXSH, respectively, as described in Rodrigues and Park (1993)
. Cells
were selected in 125 ng/ml Hygromycin B (Roche Diagnostics, Laval, PQ,
Canada), and several hundred colonies were pooled together. 293T
transient transfections were performed using calcium phosphate. Cells
were serum starved 48 h later for 20 h in DMEM containing
0.1% FBS and lysed the next day in 1.0% Triton X-100 lysis buffer as
described below.
Microinjection
MDCK cells (7 × 103) were plated on glass coverslips (Bellco Glass, Vineland, NJ) 3 days before microinjection. DNA plasmids were diluted in phosphate-buffered saline (PBS) as indicated in the figure legends. Occasionally, rabbit immunoglobulin G (Pierce, Rockford, IL) was included at a concentration of 0.6 µg/µl to detect injected cells. Small colonies of 10-50 cells were injected using an Eppendorf Micromanipulator (Eppendorf Scientific, Westbury, NY). Microinjected cells were incubated for 4 hours before stimulation with HGF for an additional 4 hours. For experiments with CrkII or CrkL, cells were incubated for 5 hours after microinjection and fixed as described below.
Indirect Immunofluorescence
Cells were fixed for 15 min in 3.7% formaldehyde and
permeabilized with 0.2% Triton X-100. For vinculin staining, cells
were incubated for 10 min in 0.25× CSK buffer (2.5 mM
1,4-piperazindiethansulfonic acid, pH 7.0, 75 mM sucrose, 12.5 mM NaCl,
0.75 mM MgCl2, and 0.125% Triton X-100) at room
temperature and then fixed as described above. Nonspecific binding
sites on the cells were blocked with 1% bovine serum albumin for 30 min. Primary and secondary antibodies were added successively, each for
30 min, with extensive washing between each incubation. HA.11
antibodies were diluted 1:300, 9E10 antibodies were diluted 1:800,
vinculin antibodies were diluted 1:400, and Crk, CrkL,
-catenin, and
E-cadherin antibodies were diluted 1:200. Secondary antibodies were
diluted 1:1000. Both AlexaFluor488 phalloidin and Texas Red-X
phalloidin were used at a 1:1000 dilution. All reagents were diluted in
PBS supplemented with 1 mM MgCl2 and 1 mM
CaCl2, with the exception of phalloidin, which
was diluted in PBS supplemented with 0.2% Triton X-100. For
experiments where cells were microinjected with rabbit immunoglobulin G, donkey
-rabbit antibodies conjugated to AlexaFluor488 were used
to detect injected cells. Coverslips were mounted onto glass slides
using Immunofluore mounting medium (ICN, St. Laurent, PQ, Canada).
Images were acquired using a Retiga 1300 digital camera (QIMAGING,
Burnaby, BC, Canada) and a Zeiss AxioVert 135 microscope (Carl Zeiss
Canada Ltd., Toronto, ON, Canada). Image analysis was carried out using
Northern Eclipse version 6.0 (Empix Imaging, Mississauga, ON, Canada).
Immunoprecipitation and Western Blotting
For coimmunoprecipitations, MDCK cells were serum starved for
20 h in DMEM containing 0.02% FBS, stimulated with 100 U/ml HGF,
and lysed in 1.0% Triton X-100 lysis buffer containing 50 mM HEPES, pH
7.5, 150 mM NaCl, 2 mM EGTA, 1.5 mM MgCl2, 1 mM
PMSF, 1 mM Na3VO4, 50 mM
NaF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. Immunoprecipitations and Western blotting were performed as described previously (Fixman et al., 1996
). The preparation of
NP40-soluble and -insoluble fractions was carried out as described in
(Potempa and Ridley, 1998
) and equal amounts of protein were used for
Western blotting with E-cadherin antibodies.
Rac1 and Rap1 Pulldown Assays
Cells were grown for 36 h in DMEM containing 10% FBS and
serum-starved in DMEM containing 0.02% FBS for 4 h before HGF
stimulation (100 U/ml). Cells were lysed in 25 mM HEPES, pH 7.5, 10 mM
MgCl2, 100 mM NaCl, 1% NP-40, and 5% glycerol
for the Rac1 pulldowns and in 50 mM TrisCl, pH 7.5, 10 mM
MgCl2, 200 mM NaCl, 1% NP-40, and 10% glycerol
for the Rap1 pulldowns. The lysis buffers included 1 mM PMSF, 1 mM
Na3VO4, 50 mM NaF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. GST-CRIB or GST-RalGDS
fusion proteins were used for Rac1 or Rap1 pulldowns, respectively.
Fusion proteins were prepared from bacteria as described previously
(Royal et al., 2000
), and 20 µg of GST fusion protein was
coupled to glutathione-Sepharose beads for 30 min at room temperature.
After two washes of the glutathione-Sepharose beads, 700 µg of cell
lysate was added to the coupled fusion proteins and incubated for 60 min at 4°C while rocking. Glutathione-Sepharose beads were washed
four times with lysis buffer, and proteins were eluted by boiling in
2× Laemmli sample buffer containing 100 mM DTT. Samples were subjected
to SDS-PAGE and Western blotted with Rac1 or Rap1 antibodies. Dr. John
Collard (The Netherlands Cancer Institute) provided GST-CRIB and Dr.
Johannes Bos (University Medical Center Utrecht) provided GST-RalGDS.
| |
RESULTS |
|---|
|
|
|---|
CrkII-associated Proteins in MDCK Cells
To examine the molecular mechanisms that regulate EM
transitions, we have used MDCK kidney epithelial cells as a model
system. In response to HGF, colonies of MDCK epithelial cells undergo multiple morphological changes leading to an EM transition and cell
dispersal. This occurs as a series of sequential events where the
centrifugal spreading of cells within the colony is concomitant with
the breakdown of cell-cell junctions and the acquisition of a motile
mesenchymal phenotype (Ridley et al., 1995
; Royal and Park,
1995
; Potempa and Ridley, 1998
). Both the CrkII and CrkL adapter
proteins coordinate cell motility (Klemke et al., 1998
;
Uemura and Griffin, 1999
; Cho and Klemke, 2000
; Petit et al., 2000
; Spencer et al., 2000
), yet their involvement
in the regulation of EM transitions has not been addressed. We and
others have demonstrated that after activation of the Met receptor
tyrosine kinase, CrkII and CrkL are recruited into Met-dependent
signaling complexes (Garcia-Guzman et al., 1999
, 2000
;
Lamorte et al., 2000
; Sakkab et al., 2000
). Both
CrkII and CrkL are expressed in MDCK epithelial cells and in
well-differentiated breast cancer cell lines that retain the ability to
grow as colonies (see Figures 1 and 6 and our unpublished results). To
assess the role of the CrkII and CrkL adapter proteins in HGF-induced
EM transition, we initially examined the profile of
phosphotyrosine-containing proteins bound to CrkII and CrkL in
serum-starved and HGF-stimulated MDCK cells. In the absence of
stimulation, CrkII and CrkL were associated with tyrosine
phosphorylated proteins, and these interactions were enhanced after HGF
stimulation (Figure 1A). Both CrkII and CrkL immunoprecipitates displayed similar phosphotyrosine profiles, with the predominant tyrosine phosphorylated proteins displaying a
molecular weight of 110-130 kDa. We examined the ability of CrkII to
associate with known Crk interacting proteins such as Gab1, Cbl, and
p130Cas, all of which are 110-130 kDa in size. For these experiments,
MDCK cells overexpressing Gab1 were used in order to detect CrkII/Gab1
coupling. CrkII displayed a similar phosphotyrosine content in both
MDCK (Figure 1A) and MDCK cells overexpressing Gab1 (Figure 1B).
Complexes of CrkII with Gab1, Cbl, and p130Cas (Figure 1B) were present
at low levels in the absence of HGF stimulation and were enhanced in
the presence of HGF (Figure 1B). Coupling of CrkII with each of these
proteins showed distinct kinetics suggesting that in response to HGF,
CrkII is recruited into multiple protein complexes. Paxillin, a known Crk-interacting protein of 68 kDa, was associated with CrkII in the
absence of stimulation, and its association was enhanced after HGF
stimulation (Figure 1B). Similar levels of CrkII were
immunoprecipitated in each sample (Figure 1B).
|
A CrkI SH3 Domain Mutant Impairs HGF-induced Cell Spreading
To examine the potential role of CrkII and CrkL in the early
biological events after HGF stimulation, MDCK cells were microinjected with empty vector or with plasmids encoding a CrkI protein with a
mutation in its SH3 domain (CrkI W170K) or with mutations in both its
SH2 and SH3 domains (CrkI R38K/W170K). CrkI is an alternatively spliced
form of CrkII that lacks the carboxy-terminal SH3 domain. The CrkI
W170K proteins contains a point mutation in its amino-terminal SH3
domain, which abolishes Crk binding to proline-rich containing proteins
(Tanaka et al., 1995
). This Crk mutant contains a functional SH2 domain that interacts with tyrosine-phosphorylated proteins and
acts as a dominant negative mutant, inhibiting the activation of ERK-1
in cells expressing an oncogenic form of Abl (Tanaka et al.,
1995
). In colonies of MDCK cells microinjected with vector (Figure
2Aa) or the CrkI SH2/SH3 mutant (CrkI
R38K/W170K, Figure 2Ag), HGF stimulation (10 U/ml) promotes
lamellipodia formation, centrifugal spreading, and loss of cortical
actin (Figure 2A, b and h). In contrast, cells microinjected with the
CrkI SH3 domain mutant (W170K, Figure 2Ad) failed to form lamellipodia
or spread in response to HGF (Figure 2Ae, arrowheads), whereas
uninjected cells in the same colony form lamellipodia and spread in
response to HGF (Figure 2Ae, arrows). Moreover, cells microinjected
with the CrkI SH3 domain mutant retained cortical actin and showed a
decreased ability to form actin stress fibers in response to HGF
(Figure 2Ae). This suggests that the
ability of Crk adapter proteins (CrkII or CrkL) to couple
tyrosine-phosphorylated proteins with downstream effectors is important
for lamellipodia formation and cell spreading in response to HGF. To
confirm that the CrkI SH3 domain mutant competes with endogenous CrkII
or CrkL for binding to tyrosine-phosphorylated proteins, 293T cells
were transiently transfected with an oncogenic form of Met (Tpr-Met)
together with empty vector or the CrkI SH3 domain mutant (W170K). The
association of CrkII and CrkL with tyrosine-phosphorylated proteins was
enhanced in the presence of Tpr-Met (Figure 2B), as observed in
HGF-stimulated MDCK cells (Figure 1, A and B). However, in the presence
of CrkI W170K, the coupling of CrkII and CrkL with
tyrosine-phosphorylated proteins was significantly diminished, in
particular, with proteins of 110-130 kDa (Figure 2B). The expression
levels of Tpr-Met and CrkI W170K are shown in Figure 2B.
|
|
Overexpression of CrkII or CrkL Promotes the Spreading of MDCK Cells
The ability of the CrkI SH3 domain mutant to block HGF-mediated
rearrangement of the actin cytoskeleton and cell spreading (Figure 2A)
prompted us to examine whether CrkII or CrkL could modulate these
responses independently of HGF. MDCK cell colonies were microinjected
with plasmids encoding wild-type CrkII or CrkL and fixed 5 hours later.
In the absence of HGF, the microinjection of CrkII (Figure 3a) or CrkL
plasmids (Figure 3d) promoted the formation of distinct membrane
extensions resembling lamellipodia in cells at the edge of the colony
(Figure 3, b and e, arrows) and the spreading of cells within the
colony (Figure 3, b and e). Moreover, cells microinjected with CrkII or
CrkL plasmids displayed the loss of cortical actin and formation of
actin stress fibers (Figure 3, b and e). Because the overexpression of
CrkII or p130Cas enhanced cell motility after transient overexpression in COS cells (Klemke et al., 1998
), we examined the ability
of p130Cas to promote cell spreading in MDCK cells. In contrast to CrkII or CrkL, the microinjection of p130Cas plasmids (Figure 3g) did
not promote lamellipodia formation or cell spreading (Figure 3h,
arrow), although the myc-tagged p130Cas was overexpressed as detected
with anti-myc immunostaining (Figure 3g). Hence, when overexpressed,
CrkII or CrkL but not p130Cas mimic the early morphological events that
occur after HGF stimulation.
Stable Overexpression of CrkII in MDCK Cells Activates Downstream Effectors, Rac1 and Rap1, and Promotes Cell Spreading
To confirm the data obtained by microinjection, we generated
stable lines of MDCK cells overexpressing CrkII (Figure
4, A and B). When compared with parental
MDCK cells (Figure 4Aa), cells overexpressing CrkII displayed enhanced
cell spreading (Figure 4Ab) and possessed large lamellipodia (Figure
4Ab, arrows) in the absence of HGF stimulation. The Crk SH3 domain
associates with DOCK180 and C3G, which activate Rac1 (Kiyokawa et
al., 1998
; Nolan et al., 1998
) and Rap1 (Gotoh et
al., 1995
), respectively. Although we were unable to detect the
association of DOCK180 with CrkII or CrkL (our unpublished results),
the association of C3G with CrkII was enhanced in MDCK cells
overexpressing CrkII (Figure 4D). To establish if downstream effectors
were activated in MDCK cells overexpressing CrkII, we evaluated
Rac1-GTP levels by pulldown assays using GST-PAK and Rap1-GTP levels by
pulldown assays using GST-RalGDS. In MDCK cells overexpressing CrkII,
Rac1-GTP levels (Figure 4C) and Rap1-GTP levels (Figure 4E) were
elevated, in comparison with parental cells.
|
Rac1 but not Rap1 Is Required for CrkII-induced Lamellipodia Formation and Cell Spreading
The activation of Rac1 is required for HGF-induced
lamellipodia formation and cell spreading (Ridley et al.,
1995
; Royal et al., 2000
), CrkII-stimulated cell migration
(Klemke et al., 1998
), and CrkII-stimulated lamellipodia
formation in single cells (Dolfi et al., 1998
; Klemke
et al., 1998
). In addition, Rap1 regulates integrin-mediated cell adhesion (Bos et al., 2001
)
and cell spreading (Ohba et al., 2001
). We proceeded to
determine whether Rac1 and/or Rap1 were required for CrkII-induced cell
spreading in MDCK cells. MDCK cells were microinjected with CrkII
plasmids together with empty vector (Figure
5, a-c), plasmids encoding a dominant
negative mutant of Rac1 (N17 Rac1, Figure 5, d-f) or plasmids encoding a dominant negative mutant of Rap1 (N17 Rap1, Figure 5, g-i). After
fixation, cells were stained with CrkII (Figure 5a) or Myc (9E10)
antibodies (Figure 5, d and g) to detect expression of dominant
negative myc-tagged Rac1 or Rap1. Expression of N17 Rac1 (Figure 5e)
but not N17 Rap1 (Figure 5h) abolished the ability of CrkII to mediate
cell spreading and lamellipodia formation. In contrast to cells
microinjected with CrkII and empty vector or N17 Rap1 (Figure 5, b and
h), cells microinjected with CrkII and dominant negative Rac1 failed to
lose their cortical actin and were unable to form stress fibers (Figure
5e). Thus, Rac1 but not Rap1 is an essential mediator of CrkII-induced
cytoskeletal rearrangements and cell spreading.
|
CrkII Promotes Loss of
-catenin from Cell-Cell Junctions
To establish whether CrkII-induced cell spreading is unique to
MDCK cells or common to other epithelial cell lines that grow as
colonies, we generated CrkII-overexpressing populations of a highly
differentiated breast cancer epithelial cell line, T47D. Interestingly,
populations of T47D cells overexpressing CrkII demonstrated enhanced
membrane ruffling (Figure 6Ab, arrows), and 82% of the colonies were dispersed (Figure 6Ab), whereas only 17%
of vector-containing cells were dispersed (Figure 6Aa). Colonies of
epithelial cells contain adherens junctions composed of E-cadherin and
-catenin and tight junctions containing ZO-1 protein complexes (reviewed in Gumbiner, 2000
). The breakdown of adherens junctions is a
necessary prerequisite for cell dispersal (Tsukamoto and Nigam, 1999
).
Therefore, we compared the localization of
-catenin in vector and
CrkII-overexpressing T47D cells. Although vector containing T47D cell
colonies exhibited well defined
-catenin staining at cell-cell
junctions (Figure 6Cb),
-catenin staining was absent from the
membrane of cells in dispersed T47D colonies overexpressing CrkII
(Figure 6Cd, arrowhead). Moreover, reduced
-catenin staining was
observed at cell-cell junctions in nondispersed T47D cells
overexpressing CrkII (Figure 6Cd, arrow). Hence, the overexpression of
CrkII promotes the loss of
-catenin-containing adherens junctions
in T47D colonies and enhances cell dispersal.
|
In contrast to T47D cells (Figure 6), MDCK cells overexpressing CrkII
are not dispersed (Figure 4A), yet they displayed reduced
-catenin
staining at cell-cell junctions (Figure
7Ad) when compared with parental cells
(Figure 7Ab). Consistent with this, E-cadherin was translocated from an
NP40-insoluble to an NP40-soluble compartment in MDCK cells
overexpressing CrkII (Figure 7B). The ability of CrkL to promote the
breakdown of epithelial adherens junctions was evaluated by
microinjecting MDCK cells with plasmids encoding CrkL. Reduced
-catenin staining at cell-cell junctions was observed in cells
microinjected with CrkL plasmids (Figure 7Cb, arrows), compared with
noninjected cells that showed no reduction in
-catenin at cell-cell
junctions (Figures 7Cb). Rac1 is present at cell-cell junctions in
MDCK cells (Royal et al., 2000
), and Rac1 activity is
involved in the assembly and breakdown of adherens junctions (Braga,
2000
). In cells microinjected with CrkII plasmids (Figure 7Da), Rac1
localization to cell-cell junctions was decreased and displayed a
diffuse cytoplasmic localization (Figure 7Db), whereas in noninjected
cells, endogenous Rac1 was retained at cell-cell junctions (Figure
7Db). The data presented in Figures 6 and 7 demonstrate that both CrkII
and CrkL can stimulate the loss of epithelial adherens junctions and
alter Rac1 localization.
|
ZO-1 Is Retained at Cell-Cell Junctions in MDCK Cells Overexpressing CrkII
We have previously shown that in MDCK cells, the HGF-stimulated
turnover of adherens junctions corresponds with cell spreading and
precedes the loss of tight junctions (Royal and Park, 1995
). Although
MDCK cells overexpressing CrkII displayed extensive cell spreading,
ZO-1 was retained at cell-cell junctions (Figure
8Ad), as with the parental MDCK cells
(Figure 8Ab). However, a minority of MDCK cells microinjected with
CrkII plasmids dispersed (Figure 8Bc). These cells exhibited loss of
ZO-1 staining at cell-cell contacts (Figure 8Bb, arrow) and showed
punctate ZO-1 staining within the cytoplasm (Figure 8Bb). In contrast,
T47D cells lack ZO-1 containing tight junctions (our unpublished
results) and the loss of
-catenin containing adherens junctions in
cells overexpressing CrkII promotes cell dispersal and conversion to a
mesenchymal like phenotype (Figure 6A).
|
Reorganization of Focal Adhesions in Cells Overexpressing CrkII
The spreading and dispersal of epithelial colonies requires
the reorganization of the actin cytoskeleton and the assembly of
nascent focal adhesions/complexes to strengthen adhesion to the
extracellular matrix (Sastry and Burridge, 2000
). MDCK and T47D cells
overexpressing CrkII were stained with vinculin antibodies and
phalloidin to visualize focal adhesions and the actin cytoskeleton, respectively. In colonies of MDCK cells, vinculin-containing adhesion complexes are prominent on cells at the edge of the colony, and only
small vinculin-containing complexes are observed throughout the colony
(Figure 9a). Consistent with the
increased spreading and lamellipodia formation observed in MDCK cells
overexpressing CrkII, vinculin-containing focal adhesions were
reorganized (Figure 9, a vs. d) and were larger in these cells (Figure
9, b vs. e, arrows). In addition, vinculin-containing focal complexes
were visible at the edge of the lamellipodia (Figure 9, d and f,
arrow). Focal adhesions present in T47D cells overexpressing CrkII were also larger in comparison with vector containing T47D cells (Figure 9,
h and i vs. k and l, arrows) and colocalized with membrane extensions
(Figure 9m, arrows). From these results we concluded that enhanced
expression of CrkII mediates the reorganization of the actin
cytoskeleton and promotes enhanced cell-matrix interactions.
|
| |
DISCUSSION |
|---|
|
|
|---|
The modulation of epithelial junctions and cell migration occurs
during normal embryonic development and participates in the dispersal
of tumor cells (Boyer et al., 2000
). The Met receptor tyrosine kinase is deregulated in many human tumors (Lamorte and Park,
2001
) and is one of the predominant mediators of EM transition (Weidner
et al., 1993
; Zhu et al., 1994
). Although several
receptor tyrosine kinases that are deregulated in human tumors
contribute to the modulation of epithelial junctions, the precise
mechanism regulating this loss is not completely understood (Boyer
et al., 2000
). The results presented here demonstrate that
the CrkII and CrkL adapter proteins play an important role in the
spreading and breakdown of epithelial cell-cell adherens junctions in
colonies of epithelial cells (Figure
10), processes critical for epithelial cell dispersal.
|
Crk Adapter Proteins Are Required for HGF-mediated Cell Spreading
The ability of a CrkI SH3 domain mutant (W170K) to block
HGF-induced cell spreading and lamellipodia formation (Figure 2A) suggests that the coupling of Crk SH2 and SH3 domains with upstream and
downstream binding proteins is an important event required for
HGF-induced cell spreading. The CrkI SH3 mutant contains an SH2 domain
but lacks functional SH3 domains, thereby acting as an isolated SH2
domain. Consistent with this, the CrkI W170K mutant competes with CrkII
and CrkL for the binding to tyrosine-phosphorylated proteins (Figure
2B). The SH2 domains of CrkII and CrkL prefer a YXXP motif and bind the
same proteins where tested (Feller, 2001
). This is further supported by
our data demonstrating that both CrkII and CrkL bind similar
phosphotyrosine-containing proteins in MDCK cells (Figure 1A). Our
loss-of-function approach using the CrkI SH3 mutant demonstrated that
both CrkII and CrkL participate in HGF-stimulated cell spreading and
breakdown of adherens junctions. This is further supported by
complementary gain-of-function experiments demonstrating the ability of
CrkII or CrkL to promote spreading of colonies of MDCK cells (Figures 3
and 4A) and dispersal of colonies of T47D breast carcinoma cells
(Figure 6A) in the absence of HGF stimulation.
The Crk SH3 domain interacts with several proteins including DOCK180,
which binds and activates Rac1 (Erickson et al., 1997
; Kiyokawa et al., 1998
), and C3G, an exchange factor for Rap1
(Gotoh et al., 1995
). Consistent with a role for Crk in
HGF-dependent cell spreading, Rac1 activity is required for both CrkII-
and HGF-stimulated cell spreading and remodeling of the actin
cytoskeleton (Figure 5 and Ridley et al. [1995] and Royal
et al. [2000], respectively). Moreover, Rac1 activity is
elevated in MDCK cells overexpressing CrkII, to levels similar to those
observed after HGF stimulation (Figure 4C). Although DOCK180 has been
shown to activate Rac1 (Kiyokawa et al., 1998
; Nolan
et al., 1998
), we have been unable to coimmunoprecipitate
either CrkII or CrkL with DOCK180 in MDCK or T47D cells (our
unpublished results). Moreover, a farnesylated form of DOCK180 that
promotes cell spreading in fibroblasts (Kiyokawa et al.,
1998
) failed to do so when microinjected into MDCK cells (our
unpublished results). Alternatively, Crk SH3 binding protein(s) distinct from DOCK180 may be involved in the activation of Rac1 in MDCK
cells. Consistent with its ability to interact with C3G, overexpression
of CrkII in MDCK cells promoted the enhanced association of CrkII with
C3G (Figure 4D) and enhanced Rap1 activity (Figure 4E). However,
whereas a dominant negative Rac1 mutant inhibited Crk- or HGF-induced
cell spreading, the overexpression of a dominant negative Rap1 mutant
failed to do so (Figure 5). Although we show that activation of Rap1 is
not required for cell spreading downstream of CrkII, Rap1 may be
important for cell migration, morphogenesis, and/or sustained ERK
activation (Bos et al., 2001
), processes not evaluated here.
We have shown that in MDCK cells, CrkII binds multiple
phosphotyrosine-containing proteins including Cbl, Gab1, paxillin, and
p130Cas (Figure 1B) and that these interactions are increased with
distinct temporal profiles after HGF stimulation (Figure 1B). In
response to HGF, the binding to one or all of these proteins may target
CrkII to the membrane and/or other cellular compartments, where Crk SH3
binding proteins can activate Rac1 and Rap1. CrkII and p130Cas each
promote the formation of lamellipodia (Dolfi et al., 1998
;
Klemke et al., 1998
) and enhance cell migration when
overexpressed in dispersed COS cells (Klemke et al., 1998
). However, overexpression of p130Cas in adhesive colonies of MDCK cells
does not promote cell spreading or lamellipodia formation (Figure 3).
Thus, although the coupling of Crk with p130Cas may be important for
cell migration once cells have adopted a mesenchymal phenotype,
overexpression of p130Cas is not sufficient for lamellipodia formation
and cell spreading in colonies of epithelial MDCK cells. Similarly, the
microinjection of plasmids expressing Gab1 or Cbl failed to induce cell
spreading and lamellipodia formation in the absence of HGF (our
unpublished results).
MDCK cells overexpressing CrkII or CrkL display numerous actin
stress fibers (Figures 3 and 9) and larger focal adhesions (Figure 9),
suggesting that RhoA is activated downstream of Crk adapter proteins.
In addition, prominent actin stress fibers are present in control cells
stimulated with HGF but not in cells microinjected with a Crk SH3
domain mutant (Figure 2Ae). Hence, the coupling of Crk adapter proteins
with SH2 and SH3 domain binding proteins may be required for RhoA
activation after HGF stimulation. This is consistent with the ability
of CrkII SH2 or SH3 domain mutants to abolish stress fiber formation in
fibroblasts (Nakashima et al., 1999
). Moreover, PC12 cells
expressing v-Crk display enhanced stress fiber and focal adhesion
formation and v-Crk activated Rho-kinase (Altun-Gultekin et
al., 1998
). Pharmacological inhibition of Rho-kinase using Y27632
decreased stress fiber formation in MDCK cells microinjected with CrkII
or CrkL but failed to inhibit cell spreading (our unpublished results).
We concluded that Rho-kinase activity and stress fiber formation are
dispensable for CrkII and CrkL-stimulated cell spreading.
Crk Adapter Proteins Stimulate the Breakdown of Epithelial Adherens Junctions
We have demonstrated for the first time that both CrkII and CrkL
induce the loss of epithelial adherens junctions when overexpressed (Figures 6C and 7). Moreover, cells microinjected with the CrkI SH3
mutant and stimulated with HGF retain cortical actin (Figure 2Ae),
demonstrating that this mutant blocks the HGF-mediated loss of adherens
junctions. In support of a role for Crk-dependent loss of adherens
junctions, less E-cadherin and
-catenin are present in the insoluble
compartment of MDCK cells overexpressing CrkII, in comparison with
control cells (Figure 7B and our unpublished results). Rac1 is involved
in both the assembly and disassembly of adherens junctions (Braga,
2000
) and regulates the clathrin-independent endocytosis of E-cadherin
(Akhtar and Hotchin, 2001
). In colonies of MDCK cells, Rac1 is
localized to cell-cell junctions and is translocated to lamellipodia
after stimulation of cells with HGF (Royal et al., 2000
). In
cells microinjected with CrkII, Rac1 is lost from cell-cell junctions
and translocates to the cytoplasm (Figure 7Db). ARF6 is required for
the targeting of Rac1 to the membrane (Radhakrishna et al.,
1999
) and for HGF-stimulated E-cadherin internalization and migration
(Palacios et al., 2001
). Moreover, overexpression of ARNO,
an ARF6 exchange factor, stimulates Rac1 activity, lamellipodia
formation, and cell dispersal in MDCK cells (Santy and Casanova, 2001
).
Hence, it will be important to establish the ability of CrkII and CrkL
to regulate ARF activity through its ability to associate with protein
complexes such as paxillin, which binds ARF GTPase-activating proteins
(reviewed in Turner et al., 2001
).
The ability of epithelial cells to detach from neighboring cells is a
prerequisite for tumor cell invasion. Although the overexpression of
CrkII in stable lines of MDCK cells promotes cell spreading (Figure 4A)
together with the loss of adherens junctions (Figure 7A), MDCK cells
remain in colonies and retain tight junctions as visualized by ZO-1
(Figure 8A). In contrast, the overexpression of CrkII in a
well-differentiated breast carcinoma cell line T47D promotes cell
dispersal (Figure 6A). Notably, T47D cells lack tight junctions
containing ZO-1 (our unpublished results), and the loss of adherens
junctions after CrkII overexpression (Figure 6C) is sufficient to
promote cell dispersal and a mesenchymal transition (Figure 6A).
Several invasive breast cancer cell lines show loss of ZO-1 (Sommers
et al., 1994
), and one study demonstrated loss of
heterozygosity in ZO-1 in 23% of breast cancer patients and reduced or
no ZO-1 staining in 69% of patients (Hoover et al., 1998
).
Hence, the loss of adherens junctions and ZO-1 containing tight
junctions may predispose cells to dispersal after deregulation of
signaling pathways involving Crk.
In conclusion, we have demonstrated that CrkII and CrkL are required
for HGF-mediated cell spreading, lamellipodia formation, and breakdown
of adherens junctions (Figure 10). Furthermore, we have shown for the
first time that CrkII and CrkL each promote the loss of adherens
junctions, which contributes to induce an EM-like transition (Figure
10), events critical for tumor cell dispersal and invasion. Our data,
together with that demonstrating that CrkII and CrkL enhance cell
migration (Klemke et al., 1998
; Uemura and Griffin, 1999
;
Cho and Klemke, 2000
; Hemmeryckx et al., 2001
), underscore
the importance of Crk adapter proteins in cancer and highlights their
suitability as therapeutic targets.
| |
ACKNOWLEDGMENTS |
|---|
The authors thank G. Vande Woude, M. Tremblay, B. Mayer, J. Groffen, A. Hall, J. Collard, J. Bos, and M. Matsuda for reagents provided in this study and C. Maroun, P. Peschard, and V. Sangwan for their insightful comments on the manuscript. L.L. is a recipient of a Canadian Institutes of Health Research studentship. M.P. is a recipient of a Canadian Institutes of Health Research scientist award. This research was supported by an operating grant to M.P. from the Canadian Breast Cancer Research Initiative.
| |
FOOTNOTES |
|---|
Corresponding author. E-mail
address: morag{at}lan1.molonc.mcgill.ca.
Present address: Ste-Justine Hospital, Department
of Pediatrics, University of Montreal, Montreal, Quebec, Canada.
Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.01-10-0477. Article and publication date are at www.molbiolcell.org/cgi/doi/10.1091/mbc.01-10-0477.
| |
ABBREVIATIONS |
|---|
Abbreviations used: EM, epithelial-mesenchymal; FBS, fetal bovine serum; HGF, hepatocyte growth factor; MDCK, Madin-Darby canine kidney; PBS, phosphate-buffered saline; PI3K, phosphatidylinositol 3'-kinase; SH2, Src homology 2; SH3, Src homology 3.
| |
REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. E. Fathers, S. Rodrigues, D. Zuo, I. V. Murthy, M. Hallett, R. Cardiff, and M. Park CrkII Transgene Induces Atypical Mammary Gland Development and Tumorigenesis Am. J. Pathol., January 1, 2010; 176(1): 446 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-T. Chiu, K.-J. Chang, C.-H. Ting, H.-C. Shen, H. Li, and F.-J. Hsieh Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells Carcinogenesis, September 1, 2009; 30(9): 1475 - 1486. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. N. Paliouras, M. A. Naujokas, and M. Park Pak4, a Novel Gab1 Binding Partner, Modulates Cell Migration and Invasion by the Met Receptor Mol. Cell. Biol., June 1, 2009; 29(11): 3018 - 3032. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Chianale, S. Cutrupi, E. Rainero, G. Baldanzi, P. E. Porporato, S. Traini, N. Filigheddu, V. F. Gnocchi, M. M. Santoro, O. Parolini, et al. Diacylglycerol Kinase-{alpha} Mediates Hepatocyte Growth Factor-induced Epithelial Cell Scatter by Regulating Rac Activation and Membrane Ruffling Mol. Biol. Cell, December 1, 2007; 18(12): 4859 - 4871. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Noren and E. B. Pasquale Paradoxes of the EphB4 Receptor in Cancer Cancer Res., May 1, 2007; 67(9): 3994 - 3997. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Leibowitz-Amit, G. Tsarfaty, Y. Abargil, G. M. Yerushalmi, J. Horev, and I. Tsarfaty Mimp, a Mitochondrial Carrier Homologue, Inhibits Met-HGF/SF-Induced Scattering and Tumorigenicity by Altering Met-HGF/SF Signaling Pathways. Cancer Res., September 1, 2006; 66(17): 8687 - 8697. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mood, C. Saucier, Y.-S. Bong, H.-S. Lee, M. Park, and I. O. Daar Gab1 Is Required for Cell Cycle Transition, Cell Proliferation, and Transformation Induced by an Oncogenic Met Receptor Mol. Biol. Cell, September 1, 2006; 17(9): 3717 - 3728. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Watanabe, M. Tsuda, Y. Makino, S. Ichihara, H. Sawa, A. Minami, N. Mochizuki, K. Nagashima, and S. Tanaka Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor-Induced Cell Motility of Human Synovial Sarcoma Cell Lines Mol. Cancer Res., July 1, 2006; 4(7): 499 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Suzuki, H. Mimuro, T. Suzuki, M. Park, T. Yamamoto, and C. Sasakawa Interaction of CagA with Crk plays an important role in Helicobacter pylori-induced loss of gastric epithelial cell adhesion J. Exp. Med., November 7, 2005; 202(9): 1235 - 1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Abella, P. Peschard, M. A. Naujokas, T. Lin, C. Saucier, S. Urbe, and M. Park Met/Hepatocyte Growth Factor Receptor Ubiquitination Suppresses Transformation and Is Required for Hrs Phosphorylation Mol. Cell. Biol., November 1, 2005; 25(21): 9632 - 9645. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Deng, J. Sun, and J. T. Barbieri Uncoupling Crk Signal Transduction by Pseudomonas Exoenzyme T J. Biol. Chem., October 28, 2005; 280(43): 35953 - 35960. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Rodrigues, K. E. Fathers, G. Chan, D. Zuo, F. Halwani, S. Meterissian, and M. Park CrkI and CrkII Function as Key Signaling Integrators for Migration and Invasion of Cancer Cells Mol. Cancer Res., April 1, 2005; 3(4): 183 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Prindull and D. Zipori Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm Blood, April 15, 2004; 103(8): 2892 - 2899. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Wang, D. Wang, and Y.-Q. Chen Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase Carcinogenesis, August 1, 2003; 24(8): 1291 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lamorte, S. Rodrigues, V. Sangwan, C. E. Turner, and M. Park Crk Associates with a Multimolecular Paxillin/GIT2/{beta}-PIX Complex and Promotes Rac-dependent Relocalization of Paxillin to Focal Contacts Mol. Biol. Cell, July 1, 2003; 14(7): 2818 - 2831. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takino, M. Nakada, H. Miyamori, J. Yamashita, K. M. Yamada, and H. Sato CrkI Adapter Protein Modulates Cell Migration and Invasion in Glioblastoma Cancer Res., May 1, 2003; 63(9): 2335 - 2337. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Maroun, M. A. Naujokas, and M. Park Membrane Targeting of Grb2-associated Binder-1 (Gab1) Scaffolding Protein through Src Myristoylation Sequence Substitutes for Gab1 Pleckstrin Homology Domain and Switches an Epidermal Growth Factor Response to an Invasive Morphogenic Program Mol. Biol. Cell, April 1, 2003; 14(4): 1691 - 1708. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lamorte, S. Rodrigues, M. Naujokas, and M. Park Crk Synergizes with Epidermal Growth Factor for Epithelial Invasion and Morphogenesis and Is Required for the Met Morphogenic Program J. Biol. Chem., September 27, 2002; 277(40): 37904 - 37911. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||